Association between plasma vitamin B5 and coronary heart disease: Results from a case-control study

Pengfei Sun1†, Haoyu Weng1†, Fangfang Fan1, Nan Zhang1, Zhihao Liu1, Ping Chen2, Jia Jia1, Bo Zheng1, Tieci Yi1, Yuxi Li1, Yan Zhang1,3‡ and Jianping Li1,3‡

1Department of Cardiology, Peking University First Hospital, Beijing, China, 2School of Pharmacy, Jinan University, Guangzhou, China, 3Key Laboratory of Molecular Cardiovascular Science of Ministry of Education, Peking University, Beijing, China

Aim: The relationship of vitamin B5 and coronary heart disease (CHD) is still uncertain. This case–control study was performed to evaluate the relationship between the plasma vitamin B5 concentration and the risk of CHD.

Materials and methods: The study involved 429 patients with >70% stenosis of the coronary arteries on coronary angiography and 429 matched controls were included for age ± 2 years, gender, and date of coronary angiography examination ± 180 days. Logistic regression analyses were performed to evaluate the association between plasma vitamin B5 and the risk of CHD.

Results: An L-shaped relationship was found between the plasma vitamin B5 concentration and CHD. Compared with patients with low vitamin B5 (first quartile, <27.6 ng/ml), the odds ratio (OR) and 95% confidence interval (CI) for participants in the third quartile (34.9–44.0 ng/ml) and fourth quartile (≥44.0 ng/ml) were 0.42 (95% CI, 0.26–0.70) and 0.49 (95% CI, 0.29–0.82), respectively. In the threshold effect analysis, the risk of CHD significantly decreased as the vitamin B5 concentration increased (per 10 ng/ml increment: OR, 0.71; 95% CI, 0.57–0.89) in participants with a plasma vitamin B5 concentration of <40.95 ng/ml; however, an increased plasma vitamin B5 concentration was no longer associated with a decreased risk of CHD (per 10 ng/ml increment: OR, 1.00; 95% CI, 0.87–1.14) in participants with a plasma vitamin B5 concentration of ≥40.95 ng/ml. The association between vitamin B5 and CHD was stronger in ever or current smokers than non-smokers (p-interaction = 0.046).

Conclusion: Plasma vitamin B5 has an L-shaped relationship with CHD, with a threshold around 40.95 ng/ml. This association was modified by smoking.

KEYWORDS
vitamin B5 (pantothenic acid), coronary heart disease, smoking, case control, L-shaped relationship
Introduction

In spite of the improvements in prevention and treatment, coronary heart disease (CHD) remains one of the most common non-communicable diseases and leading cause of death globally (1). The burden of CHD is also increasing in Chinese population in recent decades (2). The prevalence of ischemic heart disease (IHD) nearly doubled since 1990, reaching approximately 23 million in 2016 (2).

At present, identification and management of traditional risk factors for CHD are the main focus of the clinical guidelines, including smoking, dyslipidemia, hypertension, obesity, diabetes, and physical inactivity (3–6). However, in light of rising CHD prevalence and recognition of residual risk despite the effort to control traditional risk factors, there is a clear need to explore non-traditional risk or protective factors. In this regard, a better understanding the role of micronutrients is highlighted by the US precision nutrition initiative (7).

Along this line, vitamin B5 is of considerable interest. It belongs to the family of water-soluble B vitamin, also known as pantothenic acid or pantothenate or "anti-stress vitamin" (8, 9). Vitamin B5 was first discovered by Williams et al. (10) in 1933 as an essential nutrient for yeast. One important fact is that vitamin B5 must be obtained from various dietary sources or intestinal bacteria, because human body cannot synthesize B5 (11). The vitamin B5 obtained from food is in the form of coenzyme A (12). Therefore, clinicians infrequently encounter vitamin B5 deficiency, the clinical manifestations of which include generalized malaise, burning foot syndrome (13), insomnia, and autoimmune arthritis (14). Vitamin B5 can also be obtained from intestinal bacterial sources, suggesting that the intestinal microbiome might impact the concentration of vitamin B5 in plasma (12, 15).

The importance of vitamin B5 is dictated by its role in cellular metabolism. It is the key precursor to the biosynthesis of coenzyme A, which is important in the synthesis and degradation of fatty acids, synthesis of phospholipids, synthesis of heme, and operation of the tricarboxylic acid cycle (16, 17). Furthermore, pantethine, the disulfide derivative of vitamin B5, can reduce the concentrations of low-density lipoprotein cholesterol (LDL-C), very-low-density lipoprotein (VLDL), total cholesterol, triglyceride, and apolipoprotein B and increase the concentrations of high-density lipoprotein cholesterol and apolipoprotein A-1 (18). Therefore, it has been regarded as a nutritional supplement in the United States since 1992 (15). Pantethine is well-tolerated and has a low occurrence (3.6%) of mild gastrointestinal adverse effects (19). Pantethine can also reportedly improve the function of platelet, exert an antioxidant effect, protect the endothelium (20, 21), modify lipid deposition, and reduce fatty streak formation in major arteries (18, 22). Vitamin B5 deficiency may be related to a relative "hyperadrenergic" state, increasing the risk of hypertension, arrhythmia, stroke, and some other diseases (14). Moreover, dexpanthenol, the precursor to vitamin B5, is reportedly beneficial in rats with ischemia–reperfusion injury of the brain and cardiovascular system (23). According to several studies, vitamin B5 might also be related to obesity (24) and visceral fat accumulation (VFA) (25). There are also reports on the association between B5 and hypertension (26, 27). Previous study had also stated a dietary multivitamin, multiminerol and phytonutrient supplement, which contained vitamin B5, could lower homocysteine level (28).

When it comes to CHD, there are many unsettled questions regarding the role of vitamin B5. This case-control study sought to advance our understanding on the association of vitamin B5 with risk of CHD in Chinese men and women undergoing coronary angiography by involving patients with CHD and matched controls from hospital, with a particular attention to the effect modification by or joint effects with traditional CVD risk factors.

Materials and methods

Study participants

Participants were enrolled from 1 January 2016 to 31 December 2019 in Peking University First Hospital, Beijing, China. A case-control study design was used. The inclusion criteria were examination by coronary angiography, provision of written informed consent, and storage of frozen blood samples in the Peking University First Hospital biorepository. Exclusion criteria were as follows: a history of physician diagnosed CHD; serum cardiac troponin (cTnI) ≥ 0.04 ng/ml; inability to provide informed consent; refusal to supply a venous blood sample. One thousand nine hundred and sixty six individuals were included. Then a CHD case was defined as a patient with ≥ 70% stenosis of the coronary arteries on coronary angiography by involving patients with CHD and non-CHD controls were defined as a patient with <30% coronary stenosis. In total, we matched 429 patients with CHD with an equal number of controls for age ± 2 years, gender, and date of coronary angiography examination ± 180 days. Figure 1 showed the flow chat of the enrollment. All participants provided written informed consent, and the study protocol was approved by the ethics committee of both Peking University and Peking University First Hospital. The study was conducted in accordance with the Declaration of Helsinki.

Measurement of vitamin B5 and covariates

The plasma vitamin B5 concentration was measured using liquid chromatography tandem mass spectrometry. The linear
range for plasma vitamin B5 was 2.5–1,000 ng/ml. The precision within and between batches was <15%.

For each participant, we reviewed the medical records and abstracted the following variables: gender; age; height; weight and body mass index (BMI); date of coronary angiography examination; systolic blood pressure (SBP); fasting plasma glucose (FPG) concentration; plasma creatinine concentration; plasma LDL-C concentration; plasma homocysteine concentration; smoking status (current, never, or ever); drinking status (current, never, or ever); diagnosis of hypertension, diabetes, and dyslipidemia; and use of antihypertensive, hypoglycemic, and lipid-lowering drugs.

### Statistical analysis

Continuous data are presented as mean ± standard deviation for normally distributed variables and as median (interquartile range) for non-normally distributed variables. Categorical variables are presented as number and percentage. Differences between two groups were compared using t-tests for normally distributed continuous variables including age, BMI, SBP, LDL-C, FPG, Crea; Mann–Whitney U-test for non-normally distributed continuous variables including homocysteine, VB5; and χ² tests for categorical variables including smoking status, drinking status, diagnosis of disease, medication.

Odds ratios (ORs) and 95% confidence intervals (CIs) of CHD were estimated by modeling the plasma vitamin B5 concentration as continuous as well as categorical variables using conditional logistic regression, conditioned on the matching factors of age, gender, and operation time with and without adjusting for BMI; SBP; FPG; smoking status; drinking status; discharge diagnosis of hypertension, diabetes, and dyslipidemia; use of antihypertensive, hypoglycemic, and lipid-lowering drugs; LDL-C concentration, and plasma creatinine concentration. We also assessed the possible modifications of the association between the plasma vitamin B5 concentration and CHD by including interaction terms in the logistic regression models. Interactions between subgroups and the vitamin B5 concentration were examined by likelihood ratio testing. A smoothing function and two-piecewise linear regression model were used to examine the threshold effect of the plasma vitamin B5 concentration on CHD. A two-tailed p-value of <0.05 was considered statistically significant.
TABLE 1 Characteristics of cases and controls.

| Characteristics                  | Total    | Non-CHD controls | CHD cases | P-valueb |
|----------------------------------|----------|------------------|-----------|----------|
| N                                | 858      | 429              | 429       |          |
| Female, n (%)                    | 456 (53.1)| 228 (53.1)       | 228 (53.1)| 1        |
| Age, years                       | 63.5 ± 10.4| 63.1 ± 10.3     | 63.9 ± 10.5| 0.241    |
| BMI, kg/m²                       | 26.1 ± 3.7| 26.2 ± 3.7       | 25.9 ± 3.7| 0.298    |
| SBP mm Hg                        | 133.0 ± 15.8| 132.4 ± 15.6    | 133.6 ± 16.1| 0.262    |
| LDL-C, mmol/l                    | 2.3 ± 0.8| 2.4 ± 0.8       | 2.3 ± 0.8| 0.05     |
| FPG, mmol/l                      | 7.0±3.0  | 6.5 ± 2.5       | 7.5 ± 3.4| <0.001   |
| Crea, μ mol/l                    | 82.0 ± 49.3| 80.2 ± 53.3     | 83.8 ± 45.0| 0.276    |
| Homocysteine, μ mol/l            | 13.4 (10.3, 17.3)| 13.5 (10.0, 17.7)| 13.4 (10.5, 16.9)| 0.859    |
| Smoking status, n (%)            |          |                  |           | 0.005    |
| Never                            | 499 (59.4)| 272 (64.6)       | 227 (54.2)|          |
| Ever                             | 158 (18.8)| 64 (15.2)        | 94 (22.4)|          |
| Current                          | 183 (21.8)| 85 (20.2)        | 98 (23.4)|          |
| Drinking status, n (%)           |          |                  |           | 0.988    |
| Never                            | 590 (70.9)| 297 (70.7)       | 293 (71.1)|          |
| Ever                             | 82 (9.9) | 42 (10.0)        | 40 (9.7) |          |
| Current                          | 160 (19.2)| 81 (19.3)        | 79 (19.2)|          |
| Diagnosis of disease, n (%)      |          |                  |           |          |
| Hypertension                     | 600 (69.9)| 280 (65.3)       | 320 (74.6)| 0.003    |
| Diabetes                         | 361 (42.1)| 139 (32.4)       | 222 (51.7)| <0.001   |
| Dyslipidemia                     | 669 (78.0)| 317 (73.9)       | 352 (82.1)| 0.004    |
| Medication, n (%)                |          |                  |           |          |
| Antihypertensive                 | 476 (55.5)| 226 (52.7)       | 250 (58.3)| 0.099    |
| Hypoglycemia                     | 263 (30.7)| 97 (22.6)        | 166 (38.7)| <0.001   |
| Lipid-lowering                   | 411 (47.9)| 171 (39.9)       | 240 (55.9)| <0.001   |
| V5, ng/ml                        | 34.9 (27.6, 44.0)| 36.9 (29.2, 44.7)| 33.3 (26.7, 42.7)| 0.006    |

*Normally distributed variables were presented as mean ± standard deviation, non-normally were presented as median (interquartile range) and categorical variables are presented as number and percentage. bDifferences between two groups were compared using t-tests for normally distributed continuous variables, Mann–Whitney U-test for non-normally distributed continuous variables and χ² tests for categorical variables. VB5, vitamin B5; CHD, coronary heart disease; BMI, body mass index; SBP, systolic blood pressure; LDL-C, low-density lipoprotein cholesterol; FPG, fast plasma glucose; Crea, plasma creatinine; HTD, hypertension drugs.

Results

Patient characteristics

This case–control study involved 429 cases and 429 matched controls and the characteristics of both groups were showed in Table 1. The median plasma vitamin B5 concentration was 33.3 ng/ml (interquartile range, 26.7–42.7 ng/ml) among CHD cases, and 36.9 ng/ml (interquartile range, 29.8–45.1 ng/ml) among controls. CHD cases had a higher FPG concentration, lower frequency of current smoking, lower plasma vitamin B5 concentration, and higher frequency of hypertension, diabetes, plasma homocysteine levels and hyperlipidemia. Participants’ characteristics at different plasma vitamin B5 concentrations are shown Supplementary Table 1, and participants’ characteristics stratified by smoking status are shown Supplementary Table 2.

Association between plasma vitamin B5 and coronary heart disease

In Figure 2 we showed the smoothing curve between the plasma vitamin B5 concentration and CHD in overall sample (Figure 2A) and stratified by smoking status (Figure 2B), adjusted for gender; age; BMI; SBP; FPG concentration; drinking status; discharge diagnosis of hypertension, diabetes, and dyslipidemia; LDL-C concentration; and plasma creatinine concentration. The smooth curve shows an L-shaped relationship between the plasma vitamin B5 concentration and CHD in overall sample. 

In Table 2 we summarized the univariate and multivariate OR (95% CI) of CHD in relation to the plasma vitamin B5 concentration (as a categorical variable and in quartiles) in overall sample and stratified by gender. In overall sample,
compared with patients with a low vitamin B5 concentration (first quartile, $<27.6$ ng/ml), the OR (95% CI) for participants in the third quartile ($34.9–44.0$ ng/ml) and fourth quartile ($≥44.0$ ng/ml) was 0.42 (95% CI, 0.26–0.70) and 0.49 (95% CI, 0.29–0.82), respectively. In males, compared with patients with a low vitamin B5 concentration (first quartile, $<27.6$ ng/ml), the OR (95% CI) for participants in the third quartile ($34.9–44.0$ ng/ml) and fourth quartile ($≥44.0$ ng/ml) was 0.27 (95% CI, 0.12–0.62) and 0.29 (95% CI, 0.13–0.66), respectively. In females, this association was insignificant, although the gender interaction effect was insignificant ($p = 0.067$).

Although higher plasma vitamin B5 quartiles were associated with a lower frequency of CHD, a threshold effect was found for this association. In the threshold effect analysis, the risk of CHD significantly decreased as the plasma vitamin B5 concentration increased (per-10 ng/ml increment: OR, 0.71; 95% CI, 0.57–0.89) in participants with a plasma vitamin B5 concentration of $<40.95$ ng/ml; however, increased plasma vitamin B5 was no longer associated with a decreased risk of CHD (per 10 ng/ml increment: OR, 1.00; 95% CI, 0.87–1.14) in participants with a plasma vitamin B5 concentration of $≥40.95$ ng/ml. The $p$ of the log likelihood ratio test comparing the two-piecewise model with the linear logistic regression model was 0.026 (Table 3).

Subgroup and interaction analyses

In the stratified analyses to assess the relationship between the plasma vitamin B5 concentration ($<27.6$ vs. $≥27.6$ ng/ml) and CHD in the various subgroups, none of the following variables significantly modified the association between vitamin B5 and CHD: age ($<60$ vs. $≥60$ years, $p$-interaction = 0.346); gender ($p$-interaction = 0.067); BMI ($<24$, 24–28, and $≥28$ kg/m$^2$, $p$-interaction = 0.698); alcohol drinking status (never, ever, or current; $p$-interaction = 0.402); plasma creatinine concentration ($<82$ vs. $≥82$ μmol/l, $p$-interaction = 0.238); and diagnosis of hypertension (no or yes, $p$-interaction = 0.837), diabetes (no or yes, $p$-interaction = 0.686), and dyslipidemia (no or yes, $p$-interaction = 0.807). However, the smoking status modified the association between vitamin B5 and the risk of CHD, the association between vitamin B5 and CHD was stronger in ever or current smokers than non-smokers ($p$-interaction = 0.046, Table 4). Participants’ characteristics stratified by smoking status are shown Supplementary Table 2.

Discussion

To our knowledge, there are limited studies that specifically examined vitamin B5 and CHD. From mechanistic perspective, our study findings are biologically plausible. The possible mechanism between vitamin B5 and CHD can be postulated to involve inflammatory events. It is widely accepted that CHD manifests with chronic low-grade inflammation, while vitamin B5 has an antioxidant effect in the inflammatory process underlying the pathogenesis of atherosclerosis (8). Jung et al. (29) reported that high dietary vitamin B5 intake was significantly related to a lower serum C-reactive protein (CRP) concentration at the 5 years follow-up in South Korea; CRP
### TABLE 2 Association of vitamin B5 with risk of coronary heart disease (CHD).

| VB5, ng/ml | Cases (%) | Model 1<sup>a</sup> |  | Model 2<sup>b</sup> |  |
|------------|-----------|----------------------|---|----------------------|---|
| **Overall sample** |  |  |  |  |  |
| Quartiles |  |  |  |  |  |
| Q1 (<27.6 ng/ml) | 126 (58.6) | Ref |  | Ref |  |
| Q2 (27.6–34.9 ng/ml) | 110 (51.4) | 0.77 (0.53, 1.11) | 0.161 | 0.70 (0.42, 1.15) | 0.155 |
| Q3 (34.9–44.0 ng/ml) | 94 (43.9) | 0.55 (0.38, 0.81) | 0.003 | 0.42 (0.26, 0.70) | <0.001 |
| Q4 (≥44.0 ng/ml) | 99 (46.0) | 0.61 (0.41, 0.89) | 0.010 | 0.49 (0.29, 0.82) | 0.007 |
| Categories |  |  |  |  |  |
| Q1 (<27.6 ng/ml) | 126 (58.6) | Ref |  | Ref |  |
| Q2–Q4 (≥27.6 ng/ml) | 303 (47.1) | 0.64 (0.47, 0.88) | 0.005 | 0.53 (0.35, 0.80) | 0.002 |
| **Male** |  |  |  |  |  |
| Quartiles |  |  |  |  |  |
| Q1 (<27.6 ng/ml) | 71 (65.1) | Ref |  | Ref |  |
| Q2 (27.6–34.9 ng/ml) | 50 (50.0) | 0.54 (0.31, 0.95) | 0.034 | 0.40 (0.19, 0.87) | 0.020 |
| Q3 (34.9–44.0 ng/ml) | 39 (41.9) | 0.36 (0.20, 0.66) | <0.001 | 0.27 (0.12, 0.62) | 0.002 |
| Q4 (≥44.0 ng/ml) | 41 (41.0) | 0.36 (0.20, 0.64) | <0.001 | 0.29 (0.13, 0.66) | 0.003 |
| Categories |  |  |  |  |  |
| Q1 (<27.6 ng/ml) | 71 (65.1) | Ref |  | Ref |  |
| Q2–Q4 (≥27.6 ng/ml) | 130 (44.4) | 0.42 (0.26, 0.68) | <0.001 | 0.32 (0.17, 0.62) | <0.001 |
| **Female** |  |  |  |  |  |
| Quartiles |  |  |  |  |  |
| Q1 (<27.6 ng/ml) | 55 (51.9) | Ref |  | Ref |  |
| Q2 (27.6–34.9 ng/ml) | 60 (52.6) | 1.04 (0.64, 1.72) | 0.865 | 1.17 (0.56, 2.44) | 0.669 |
| Q3 (34.9–44.0 ng/ml) | 55 (45.5) | 0.77 (0.46, 1.28) | 0.317 | 0.55 (0.27, 1.12) | 0.102 |
| Q4 (≥44.0 ng/ml) | 58 (50.4) | 0.95 (0.57, 1.60) | 0.852 | 0.83 (0.38, 1.80) | 0.643 |
| Categories |  |  |  |  |  |
| Q1 (<27.6 ng/ml) | 55 (51.9) | Ref |  | Ref |  |
| Q2–Q4 (≥27.6 ng/ml) | 173 (49.4) | 0.91 (0.60, 1.38) | 0.673 | 0.79 (0.44, 1.41) | 0.419 |

<sup>a</sup>Conditioned on the matching factors of age, gender, and operation time. <sup>b</sup>Conditioned on the matching factors of age, gender, and operation time and adjusted for BMI; SBP; fasting plasma glucose concentration; smoking status; drinking status; diagnosis of hypertension, diabetes, and dyslipidemia; LDL-C concentration; plasma creatinine concentration; and use of antihypertensive, hypoglycemic and lipid-lowering medications. VB5, vitamin B5; CHD, coronary heart disease; OR, odds ratio; CI, confidence interval; Ref, reference; BMI, body mass index; SBP, systolic blood pressure; LDL-C, low-density lipoprotein cholesterol.

### TABLE 3 Threshold effect analysis of vitamin B5 (per 10 ng/ml) on coronary heart disease (CHD) using piecewise logistic regression.

| Threshold effect analysis | B | SE | Exp (B) | Z value | OR (95% CI) | P |
|---------------------------|---|----|--------|--------|-------------|---|
| **Model comparison** |  |  |  |  |  |  |
| Model I |  |  |  |  |  |  |
| One line model | −0.12 | 0.05 | 0.89 | −2.22 | 0.89 (0.80, 0.99) | 0.026 |
| Model II |  |  |  |  |  |  |
| VB5 turn point (K) |  |  |  |  |  |  |
| <K, effect 1 | −0.34 | 0.11 | 0.71 | −2.98 | 0.71 (0.57, 0.89) | 0.003 |
| >K, effect 2 | 0 | 0.07 | 1 | −0.07 | 1.00 (0.87, 1.14) | 0.945 |
| Log likelihood ratio test |  |  |  |  |  |  |
| P value | 0.026 |  |  |  |  |  |

Adjustment was performed for gender, age, BMI, SBP, fasting plasma glucose concentration; smoking status; drinking status; diagnosis of hypertension, diabetes, and dyslipidemia; LDL-C concentration; plasma creatinine concentration; and use of antihypertensive, hypoglycemic, and lipid-lowering medications. CHD, coronary heart disease; OR, odds ratio; CI, confidence interval; Ref, reference; BMI, body mass index; SBP, systolic blood pressure; LDL-C, low-density lipoprotein cholesterol. A smoothing function and two-piecewise logistics regression model were used to examine the threshold effect of the plasma VB5 concentration on CHD. The turning point was determined using trial and error, including selection of turning points along a predefined interval and then choosing the turning point that gave the maximum model likelihood. A log likelihood ratio test was used to compare the two-piecewise model with the linear logistic regression model.
TABLE 4  Subgroup and interaction analyses for the association between vitamin B5 (quartiles 2–4 vs. 1) and coronary heart disease (CHD).

| Subgroup | B5 Q1 (<27.6 ng/ml) case (%) | B5 Q2–4 (≥27.6 ng/ml) case (%) | OR (95% CI) | P | P-interaction |
|----------|-----------------------------|-------------------------------|-------------|---|---------------|
| Gender   |                             |                               |             |   |               |
| Male     | 71 (65.1)                   | 130 (44.4)                    | 0.39 (0.23, 0.67) | < 0.001 |               |
| Female   | 55 (51.9)                   | 173 (49.4)                    | 0.77 (0.47, 1.26) | 0.302 |               |
| Age, years |                              |                               |             |   |               |
| <60      | 55 (59.1)                   | 76 (41.5)                     | 0.45 (0.25, 0.80) | 0.007 |               |
| ≥60      | 71 (58.2)                   | 227 (49.3)                    | 0.64 (0.40, 1.01) | 0.054 |               |
| BMI, Kg/m^2 |                               |                               |             |   |               |
| <24      | 38 (58.5)                   | 86 (51.8)                     | 0.69 (0.35, 1.34) | 0.271 |               |
| 24–28    | 58 (59.2)                   | 134 (46.9)                    | 0.48 (0.28, 0.82) | 0.007 |               |
| ≥28      | 27 (56.2)                   | 80 (44.2)                     | 0.59 (0.29, 1.22) | 0.155 |               |
| Crea, µ mol/l |                             |                               |             |   |               |
| <82      | 89 (57.4)                   | 174 (43.7)                    | 0.48 (0.31, 0.74) | < 0.001 |               |
| ≥82      | 37 (62.7)                   | 128 (52.9)                    | 0.78 (0.40, 1.53) | 0.468 |               |
| Smoking status |                           |                               |             |   |               |
| Never    | 50 (45.5)                   | 177 (45.5)                    | 0.82 (0.51, 1.31) | 0.402 |               |
| Ever     | 29 (74.4)                   | 135 (54.6)                    | 0.26 (0.10, 0.67) | 0.006 |               |
| Current  | 42 (70)                     | 56 (45.3)                     | 0.39 (0.19, 0.81) | 0.011 |               |
| Drinking status |                        |                               |             |   |               |
| Never    | 80 (54.1)                   | 213 (48.2)                    | 0.65 (0.42, 0.99) | 0.046 |               |
| Ever     | 14 (70)                     | 26 (41.9)                     | 0.30 (0.09, 1.02) | 0.054 |               |
| Current  | 26 (65)                     | 53 (44.2)                     | 0.44 (0.19, 1.01) | 0.052 |               |
| Hypertension |                              |                               |             |   |               |
| No       | 43 (53.1)                   | 66 (37.3)                     | 0.53 (0.29, 0.97) | 0.04 |               |
| Yes      | 83 (61.9)                   | 237 (50.9)                    | 0.58 (0.37, 0.91) | 0.019 |               |
| Diabetes |                             |                               |             |   |               |
| No       | 70 (49.3)                   | 137 (38.6)                    | 0.59 (0.38, 0.92) | 0.02 |               |
| Yes      | 56 (76.7)                   | 166 (57.6)                    | 0.51 (0.27, 0.96) | 0.036 |               |
| Dyslipidemia |                           |                               |             |   |               |
| No       | 25 (51)                     | 52 (37.1)                     | 0.52 (0.25, 1.09) | 0.084 |               |
| Yes      | 101 (60.8)                  | 251 (49.9)                    | 0.58 (0.38, 0.87) | 0.009 |               |

Adjusted, if not stratified, for gender; age; BMI; SBP; fasting plasma glucose concentration; smoking status; drinking status; diagnosis of hypertension, diabetes, and dyslipidemia; LDL-C concentration; plasma creatinine concentration; and use of antihypertensive, hypoglycemic, and lipid-lowering medications. OR, odds ratio; CI, confidence interval; CHD, coronary heart disease; BMI, body mass index; SBP, systolic blood pressure; LDL-C, low-density lipoprotein cholesterol; FPG, fasting plasma glucose; Crea, plasma creatinine; Q1, quartile 1; Q2–4, quartile 2–4.

can directly bind LDL-C and is involved in the formation of foam cells in the inflammatory process. Additionally, the findings of Scheurig et al. (30) indicated that multivitamin supplements, including vitamin B5, were associated with lower CRP concentrations among female patients. He et al. (31) stated that vitamin B5 might promote neutrophils to secrete anti-inflammatory cytokines to reduce the recruitment or activation of macrophages in early infection. In this way, vitamin B5 might regulate the macrophages in the early process of atherosclerosis.

In support of our findings, previous studies showed that vitamin B5 is also associated with several risk factors of CHD, such as dyslipidemia, hypertension, and obesity. An association between vitamin B5 and the lipid-regulating effect of pantethine has been supported by some experiments (18, 19). A randomized controlled trial by Evans et al. (15) also suggested that pantetheine, synthesized from vitamin B5 in the body, can lower the concentrations of total cholesterol, LDL-C, very-low-density lipoprotein, and triglycerides in patients with a low to moderate risk of CVD. Although the mechanism underlying the ability of pantetheine to reduce blood lipids is unclear, dyslipidemia plays a major role in the development of CVD (32). In the present study, the diagnosis of CHD in all participants was based on coronary angiography, which is more accurate than other methods.

Vitamin B5 was also proven to be associated with hypertension in some animal experiments (33–35). Koyanagi et al. (26) reported that residents with lower serum vitamin B5 concentrations living in rice field areas were more likely to be...
study was well-designed by including a relatively large number of patients with comprehensive clinical data, which made the results more credible.

A few limitations of this study require mentioning. First, this is a case–control study, and we can’t get a causal relationship between vitamin B5 and CHD. Hence, further epidemiological studies and subsequent clinical trials should be conducted to examine the role of vitamin B5 in the development of CHD. Second, selection bias inevitably exists, although we used strict statistical matching of age, gender, and the date of the coronary angiography examination to minimize confounders and maximize comparability. Third, methodological biases exist. We could not include all the confounders in the regression models. But we looked through all the variables that we could get from the electrical medical records and include variables that could have an effect on vitamin B5 or CHD. Fourth, our study is limited by the lack of long-term observation of the plasma vitamin B5 concentration. Vitamin B5 was measured only once, and potential fluctuation was not taken into account. Fifth, we did not check the vitamin B5 intake in everyday diet, and this might cause the bias. Finally, the study was carried out in a hospital setting containing only Chinese men and women, the generalizability of the study should be assessed when it applies to other populations with different characteristics in future work.

Our findings, if further confirmed by future studies, offers a new venue for preventing or treating CHD, given that vitamin B5 supplementation is simple, safe, and inexpensive. According to NIH website (40), people can obtain pantothenic acid by eating a variety of foods, including beef, poultry, seafood, organ meats, eggs and milk, vegetables such as mushrooms (especially shiitakes), avocados, potatoes, and broccoli, whole grains, such as whole wheat, brown rice and oats, peanuts, sunflower seeds, and chickpeas. If the "L" shaped association is true, it also implies that finding a dose that is appropriate for a patient is needed.

Conclusion

In summary, this hospital-based case-control study showed a significant L-shaped relationship of the plasma vitamin B5 concentration with CHD, with a threshold around 40.95 ng/ml. The smoking status significantly modified this association, which was stronger in ever or currently smoking participants. Our findings provided a new idea for preventing or treating CHD and further studies are needed to confirm.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement

The studies involving human participants were reviewed and approved by Ethics review board of Peking University First Hospital. The patients/participants provided their written informed consent to participate in this study.

Author contributions

JL and YZ designed the research and had primary responsibility for final content. ZL, JJ, BZ, and TY conducted the research. NZ provided the essential reagents, PS, FF, and YL analyzed the data and performed the statistical analysis. PS and HW wrote the manuscript. PC was responsible for the test of vitamin B5. All authors contributed to the article and approved the submitted version.

Funding

This research was funded by Projects of National Natural Science Foundation of China (grant 82070458), Capital’s Funds for Health Improvement and Research (2020-22-40714), Beijing Municipal Science and Technology Project (Z191100006619039), Key Laboratory of Molecular Cardiovascular Sciences (Peking University), and the Ministry of Education and NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides.

References

1. World Health Organization. Global Health Estimates: Life Expectancy and Leading Causes of Death and Disability. The Top 10 Causes of Death. (2020). Available online at: http://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death (accessed December 9, 2020).
2. Liu S, Li Y, Zeng X, Wang H, Yin P, Wang L, et al. Burden of cardiovascular diseases in China, 1990–2016: findings from the 2016 global burden of disease study. JAMA Cardiol. (2019) 4:342–52. doi: 10.1001/jamacardio.2019.0295
3. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J III. Factors of risk in the development of coronary heart disease–six year follow-up experience. The Framingham Study. Ann Intern Med. (1961) 55:33–50. doi: 10.7326/0003-4819:55-1-33
4. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. (2012) 33:1635–701. doi: 10.1093/eurheartj/eht092
5. Zhu N, Yu C, Guo Y, Bian Z, Han Y, Yang L, et al. Adherence to a healthy lifestyle and all-cause and cause-specific mortality in Chinese adults: a 10-year prospective study of 0.5 million people. Int J Behav Nutr Phys Act. (2019) 16:98. doi: 10.1186/s12966-019-0860-z
6. Lv J, Yu C, Guo Y, Bian Z, Yang L, Chen Y, et al. Adherence to healthy lifestyle and cardiovascular diseases in the Chinese population. J Am Coll Cardiol. (2017) 69:1116–25. doi: 10.1016/j.jacc.2016.11.076
7. Rodgers GP, Collins FS. Precision nutrition—the answer to “what to eat to stay healthy”. Jama. (2020) 324:735–6. doi: 10.1001/jama.2020.13601
8. Ghetti AA, Ghetti TA, Kenawy SA. The potential role of B5: a stitch in time and switch in cytokine. Phytother Res. (2020) 34:306–14. doi: 10.1002/ptr.6537
9. Webb ME, Smith AG, Abell C. Biosynthesis of pantothenate. Nat Prod Rep. (2004) 21:695–721. doi: 10.1039/b316419p
10. Williams RJ, Lyman CM, Goodyear GH, Truesdail JH, Holaday D. Pantothenic acid,” a growth determinant of universal biological occurrence. J Am Chem Soc. (1933) 55:2912–27. doi: 10.1021/ja01334a049
11. Wojtczak L, Slyshenkov VS. Protection by pantothenic acid against apoptosis and cell damage by oxygen free radicals—the role of glutathione. Biofactors. (2003) 17:61–73. doi: 10.1002/biof.5520170107
12. Said HM. Intestinal absorption of water-soluble vitamins in health and disease. Biochem J. (2011) 437:357–72. doi: 10.1042/BJ20110326
13. Tahiliani AG, Beinlich CJ. Pantothenic acid in health and disease. Vitam Horm. (1991) 46:165–228. doi: 10.1016/0083-6729(86)60084-6
14. Gomina KC. Vitamin D deficiency changes the intestinal microbiome reducing B vitamin production in the gut. The resulting lack of pantothenic acid adversely affects the immune system, producing a “pro-inflammatory” state associated with atherosclerosis and autoimmunity. Med Hypotheses. (2016) 94:103–7. doi: 10.1016/j.mehy.2016.07.007
15. Evans M, Rumberger JA, Anunzio I, Napolitano JI, Citrilo D, Kamiya T. Pantethine, a derivative of vitamin B5, favorably alters total, LDL and non-HDL cholesterol in low to moderate cardiovascular risk subjects eligible for statin

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.906232/full#supplementary-material

Acknowledgments

The authors gratefully acknowledge all persons involved in this study, all researchers, and all participants enrolled.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
therapy: a triple-blinded placebo and diet-controlled investigation. *Vasc Health Risk Manag.* (2014) 10:89–100. doi: 10.2147/VHRM.S57116

16. Leonard R, Jackowski S. Biosynthesis of pantothentic acid and coenzyme A. *EcoSal Plus.* (2007) 2:110.1128/ecosalplus.3.6.3.4. doi: 10.1128/ecosalplus.3.6.3.4

17. Liu YT, Jia HM, Chang X, Ding G, Zhang HW, Zou ZM. The metabolic disturbances of isoproteolen induced myocardial infarction in rats based on a tissue targeted metabolomics. *Mol Biosyst.* (2013) 9:2823–34. doi: 10.1039/c3mb70222g

18. Carrara P, Matturri L, Galbusera M, Lovati MR, Franceschini G, Sirtori CR. Pantethene reduces plasma cholesterol and the severity of arterial lesions in experimental hypercholesterolemic rabbits. *Atherosclerosis.* (1984) 53:255–64. doi: 10.1016/0021-9150(84)90126-6

19. Houston MC, Fazio S, Chilton FH, Wise DE, Jones KB, Barringer TA, et al. Nonpharmacologic treatment of dyslipidemia. *Prog Cardiovasc Dis.* (2009) 52:61–94. doi: 10.1016/j.pcad.2009.02.002

20. Qian H, Zhang Y, Wu B, Wu S, You S, Zhang N, et al. Structure and function of HECT E3 ubiquitin ligases and their role in oxidative stress. *J Transl Int Med.* (2020) 8:71–9. doi: 10.2478/jtim-2020-0012

21. Pinc JJ, Keenan JM. Dietary and nutraceutical options for managing the hyperterglycemic patient. *Prog Cardiovasc Dis.* (2006) 49:21–33. doi: 10.1016/j.pcad.2005.12.002

22. Houston M. The role of nutraceutical supplements in the treatment of dyslipidemia. *J Clin Hypertens (Greenwich)*. (2012) 14:121–32. doi: 10.1111/j.1751-7517.2011.00576.x

23. Demiriz B, Demir O, Dost T, Birincioglu M. Protective effect of vitamin B5 (dexamethasone) on cardiovascular damage induced by streptozocin in rats. *Bratisl Lek Listy.* (2014) 115:190–6. doi: 10.4149/bll_2014_040

24. Ghelamrizalzedeh M, Rastgoos S, Doaei S, Vahid F, Malmir H, Ashoori N, et al. Index of Nutritional Quality (INQ) and the risk of obesity in male adolescents: a case-control study. *BioTrace Elem Res.* (2011) 139:107–14. doi: 10.1007/s12011-02297-x

25. Ozato N, Saito S, Yamaguchi T, Katahama M, Tokuda I, Sawada K, et al. Association between nutrients and visceral fat in healthy Japanese adults: a 2-year longitudinal study brief title: micronutrients associated with visceral fat accumulation. *Nutrients.* (2019) 11:2698. doi: 10.3390/nu111112698

26. Koyanagi T, Hareyama S, Kikuchi R, Kimura T. Effect of diet on the oxidative-nitrative stress in heart of rats: prevention by folic acid. *Atherosclerosis.* (2014) 239:703–9. doi: 10.1016/j.atherosclerosis.2014.03.005

27. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. *J Am Coll Cardiol.* (2004) 43:1731–7. doi: 10.1016/j.jacc.2003.12.047

28. Sun et al. *10.3389/fcvm.2022.906232* 

29. Jung S, Kim MK, Choi BY. The long-term relationship between dietary pantothentic acid (vitamin B5): intake and C-reactive protein concentration in adults aged 40 years and older. *Nutr Metab Cardiovasc Dis.* (2017) 27:806–16. doi: 10.1016/j.numecd.2017.05.008

30. Scheurig AC, Thorand B, Fischer B, Heier M, Koenig W. Association between the intake of vitamins and trace elements from supplements and C-reactive protein: results of the MONICA/KORA Augsburg study. *Eur J Nutr.* (2008) 47:127–37. doi: 10.1007/s00394-008-0187-1

31. He W, Hu S, Xu D, Wu Q, Zhong X, Zhou X, et al. Vitamin B5 reduces bacterial growth via regulating innate immunity and adaptive immunity in mice infected with Mycobacterium tuberculosis. *Front Immunol.* (2018) 9:365. doi: 10.3389/fimmu.2018.00365

32. Grundy SM, Stone NJ, Bailey AL, Bean C, Bircher KK, Blumenthal BS, et al. 2018 AHA/ACC/AACVPR/AAPA/ACPM/ADA/AGS/APhA/ASPC/NCNBP/CNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation.* (2019) 139:e1082–143. doi: 10.1161/jacc.2018.11.002

33. Stangl E. Relationship between pantothenic acid, adrenals, and hypertension. *Acta Med Scand Suppl.* (1956) 312:61–8. doi: 10.1111/j.1600-0463.1956.tb3788.x

34. Schwabedal PE, Pietrzk K, Witikowski W. Pantothentic acid deficiency as a factor contributing to the development of hypertension. *Cardiology.* (1985) 72(Suppl 1):187–9. doi: 10.1159/000173972

35. Lewis LA, Page IH. Pantothentic acid deficiency in experimental renal hypertension in dogs. *Am J Physiol.* (1953) 173:359–63. doi: 10.1152/ajpl.1953.173.2.359

36. Kolling J, Scherer EB, Da CAA, Da CML, Wyse AT. Homocysteine induces oxidative-nitrate stress in heart of rats: prevention by folic acid. *Cardiovasc Toxicol.* (2011) 11:67–73. doi: 10.1007/s12012-010-9094-7

37. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. *J Am Coll Cardiol.* (2004) 43:1731–7. doi: 10.1016/j.jacc.2003.12.047

38. Angelina T, Jeyaraj N, Tsongalis GJ. MTHFR Gene polymorphisms, B-vitamins and hyperhomocysteinemia in young and middle-aged acute myocardial infarction patients. *Exp Mol Pathol.* (2007) 82:227–33. doi: 10.1016/j.yexmp.2007.02.005

39. Azizi-Namini P, Ahmed M, Y an AT, Keith M. The role of B vitamins in the management of heart failure. *Nutr Clin Pract.* (2012) 27:363–74. doi: 10.1177/0227194512445339

40. National Institutes of Health. *Pantothenic Acid: Fact Sheet for Consumers*. (2021). Available online at: https://ods.od.nih.gov/factsheets/PantothenicAcid-Consumer/ (accessed March 22, 2021).